Help Save Baby Kishan N
A 16-Month-Old Child Fighting a Rare Genetic Disorder
Baby Kishan N, just 16 months old, is fighting for his life after being diagnosed with Spinal Muscular Atrophy (SMA) Type 2, a rare, life-threatening genetic disorder.
This disease has been progressing rapidly over the last 2 months, and without urgent treatment, it can be fatal.
With your support, we can give Kishan a chance at life.
Samyak Chetana
About Baby Kishan N
Kishan is a cheerful 16-month-old baby whose life took a sudden turn when he was diagnosed with Spinal Muscular Atrophy (SMA) Type 2, a rare genetic condition that weakens muscles and affects basic movements such as sitting, breathing, and swallowing. and without timely treatment, it can be fatal.
What should have been a joyful phase of early childhood has now become a daily struggle for survival.
What Is Spinal Muscular Atrophy (SMA) Type 2?
Spinal Muscular Atrophy is a progressive and life-threatening genetic disease that affects the motor neurons responsible for muscle movement.
In Type 2 SMA:
Muscles gradually become weaker
Breathing and swallowing become difficult
The disease worsens over time
Without timely treatment, it can become fatal
This condition requires urgent and specialized medical intervention.
Samyak Chetana
Why Treatment Is Extremely Urgent
Doctors have confirmed that the treatment works best when given early.
Every delay reduces its effectiveness.
The prescribed medicine:
Is life-saving
Is not manufactured in India
Must be imported urgently
Is given as a single, one-time dose
Works within a limited time window
Delaying the treatment could cost Kishan his life.
One Hope: Zolgensma – A Life-Saving Gene Therapy
There is only one chance to stop the progression of this disease:
Zolgensma, a one-time gene-replacement therapy that can give Kishan a real chance at life.
This treatment can halt SMA at its root, allowing children to live longer, healthier, and more independent lives.
But this miracle comes at a heartbreaking cost—₹16 Crores.
An Impossible Amount for a Middle-Class Family
We come from a modest, middle-class background.
No sacrifice is too big when it comes to our child—but even after giving up everything we own, this amount is beyond our reach.
After much struggle, Novartis, the manufacturer of Zolgensma, has agreed to provide the medicine through an EMI plan.
Under this plan, we must pay an upfront amount of ₹9 Crores.
Our Urgent Need: ₹9 Crores to Save Kishan's Life
To begin Kishan’s treatment, we urgently need ₹9 Crores upfront.
We are reaching out to everyone we can—friends, family, organizations, and kind strangers—but we cannot do this alone.
Donate to Save Kishan’s Life
This is a race against time.
Your generosity can help a 16-month-old child survive and live a healthy life.
Account Details
Contact Details